Alterity Therapeutics Ltd

ATH - AU
Overview
Safety score
Dividends
Fundamentals
Add to watchlist

Add to calculator

Compare stock
Alterity Therapeutics Ltd
ATH
-
AU
Overview
Safety score
Dividends
Fundamentals

Overview

About stock

Health care
Sector
Biotechnology
Industry

Alterity Therapeutics Limited engages in the research and development of therapeutic drugs to treat Alzheimer's disease, Huntington disease, Parkinson's disease, and other neurological disorders in Australia. The company's lead drug candidate is ATH434 that has completed Phase I clinical trial for the treatment of Parkinson's disease. It is also developing PBT2 that has completed Phase 2a clinical trial to treat Alzheimer's disease.

The company was formerly known as Prana Biotechnology Limited and changed its name to Alterity Therapeutics Limited in April 2019.

Similar stocks

Based on sector and market capitalization

Report issue